Details for New Drug Application (NDA): 206352
✉ Email this page to a colleague
NDA 206352 describes REYATAZ, which is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from one supplier. Additional details are available on the REYATAZ profile page.
The generic ingredient in REYATAZ is atazanavir sulfate. There are twenty-five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the atazanavir sulfate profile page.
The generic ingredient in REYATAZ is atazanavir sulfate. There are twenty-five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the atazanavir sulfate profile page.
Summary for 206352
| Tradename: | REYATAZ |
| Applicant: | Bristol Myers Squibb |
| Ingredient: | atazanavir sulfate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 206352
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| REYATAZ | atazanavir sulfate | POWDER;ORAL | 206352 | NDA | E.R. Squibb & Sons, L.L.C. | 0003-3638 | 0003-3638-10 | 30 PACKET in 1 CARTON (0003-3638-10) / 1 POWDER in 1 PACKET |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL | Strength | EQ 50MG BASE/PACKET | ||||
| Approval Date: | Jun 2, 2014 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
